🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Maximal Tumor Eradication for Oligometastatic Prostate Cancer

RecruitingPhase 2, Phase 3Ages 18 Years - 75 YearsMaleRenJi Hospital
NCT06972511 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

In China, the incidence of prostate cancer is increasing in recent years, and it has ranked 5th among common male tumors and 1st in urinary tumors. Unlike developed countries in Europe and the United States, in China, because prostate-specific antigen (PSA) screening has not been widely popularized, and early prostate cancer is mostly asymptomatic, about 13%-26% of prostate cancer patients have progressed to metastatic hormone-sensitive prostate cancer (mHSPC) at the time of initial diagnosis. Compared with localized prostate cancer, the 5-year survival rate of mHSPC is only 29.3%, which is prone to symptoms such as bone pain, pathological fracture, hematuria, and dysuria and seriously decrease the survival and quality of life. As a result, it is of great significance to carry out more refined management of mHSPC, explore more scientific treatment options, and delay the time to CRPC, whi

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age less than 75 years * EORTC QLQC-30 score 2 * Life expectancy of 10 years * Patients with oligometastatic prostate cancer on clinicopathological assessment * Patients are suitable for radiotherapy and prostatectomy surgery * Patients agree to participate in the study and sign the informed consent form before enrollment Exclusion Criteria: * Tumor related fracture * Cannot accept radiotherapy * Visceral metastasis * Serious infection * Thromboembolism history * Not effectively controlled cardiovascular complications
💊

What it tests

  • neoadjuvant apatamide plus ADT + radical resection of prostate cancer + extended lymph node dissection + radiotherapy of metastases
  • Standard ADT treatment
📍

Where

1 site
RenJi hospital, school of Medicine, Shanghai Jiao Tong University
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy